Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

PaperCitations, authors & open-access status

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 49 citations, 2008 year and closed oa status.

49
Citations
2008
Year
closed
OA Status

Related on ScholarIQ

Dong Wook Kim
Author
Blood
Journal
Chronic Myeloid Leukemia Treatments
Topic
Chronic Myeloid Leukemia Treatments
Topic
Chronic Lymphocytic Leukemia Research
Topic
Eosinophilic Disorders and Syndromes
Topic
470M+ articles · free account